Fig. 5From: Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancerBrief patient case report. The timeline demonstrates that EGFR-mutated NSCLC patients benefited from combinatorial therapy with EGFR- and MET-TKIsBack to article page